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Background: Percutaneous coronary intervention (PCI) is effective therapy for significant atherosclerotic coro-
nary artery disease. Despite medical and technological advances in PCI, periprocedural myocardial infarction
(PMI) remains a common complication. The frequency and factors associated with PMI have been well investi-
gated in the developed world, yet there is a paucity of data from the developing world, especially Sub-Saharan
Africa.
Methods:Weprospectively enrolled 153 adult patients undergoing PCI at the CharlotteMaxeke Johannesburg Ac-
ademic Hospital from the 1st of February 2014 to 31st October 2014. Periprocedural Creatinine Kinase-MB and
hs-Troponin I were routinely measured before PCI and at 16–24 h post-procedure. The third universal definition
of myocardial infarction was used to define a PMI event.
Results: 152 participants met the inclusion criteria and were analysed for PMI. 70.4% participants were male. The
mean age was 58.8 (SD 10.9) years old. Sixteen (10.5%) participants fulfilled the criteria for PMI. Side branch
pinching with preserved TIMI III flow was noted in 62.5% of PMI cases. Duration of procedure (P = 0.007),
right coronary artery intervention (p=0.042) and total stent length (p=0.045)were independently associated
with PMI.
Conclusion: PMI occurred in 10.5% of cases undergoing PCI. This is consistent with the prevalence of PMI interna-
tionally. Larger multicentre studies are required in our demographic region to further define relevant predictors
and outcomes associated with PMI.
© 2016 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Coronary artery disease (CAD) has the highest global burden of
morbidity and mortality [1,2]. This is also true for the developing
worldwhere there has been significant urbanisation [3,4]. Percutaneous
coronary intervention (PCI) is a widely accepted therapeutic modality
for physiologically significant CAD [5]. Periprocedural myocardial in-
farction (PMI) is a common complication of PCI and well documented
in developed countries [6]. However, there is a paucity of data from
developing regions, especially in sub-Saharan Africa on the prevalence
of PMI despite an increasing incidence of CAD and concomitant increase
in PCI.
The aim of the current study was to define the local incidence of
PMI, to identify relevant risk factors in our study population associated
with PMI, and to compare findings to those reported in developed
regions.
2. Methods
2.1. Study design and population
This observational study was conducted from the 1st of February
2014 to 31st October 2014. One hundred and fifty-three consecutive
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and eligible patients undergoing PCI at the Charlotte Maxeke Johannes-
burg Academic Hospital (CMJAH), Johannesburg, South Africa were
prospectively recruited. This hospital is situated in the heart of Johan-
nesburg with a cardiology unit that functions as a referral point for
primary and secondary hospitals without cardiac catheterisation
capabilities. These referring hospitals are generally in the periphery of
Johannesburg and outskirts of the Gauteng province (18,176km2). As
such, the majority of acute coronary syndrome patients referred are
first treated medically in their local hospitals and then transferred to
CMJAH for coronary angiography.
The study eligibility criteria included any consenting adult in
whom PCI was planned. A baseline serum concentration of creati-
nine kinase myocardial band (CK-MB) mass and highly sensitive tro-
ponin I (hs-Tnl) (ADVIA centaur TnI –Ultra assay, Siemens
Healthcare Diagnostics Inc., NY, USA) were collected after diagnostic
coronary angiography, prior to PCI. A second cardiac biomarker was
acquired at 16–24 h post PCI in the coronary care unit. All cardiac
biomarkers were processed in the same local laboratory (National
Health Laboratory Services).
The antiplatelet regime in the cardiology unit follows recommen-
dations of the European Society of Cardiology (ESC) guidelines on
myocardial revascularisation [5]. Dual antiplatelet therapy (DAPT)
is given to patients with stable coronary artery disease (SCAD),
non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation
myocardial infarction (STEMI). All loading doses were given on
admission to the unit for all acute coronary syndromes and given
pre-PCI for SCAD requiring PCI.
In general, patients are loadedwith aspirin 300mgper os (p.o.) if not
on prior or long term aspirin therapy. This is continued with 75 mg of
aspirin p.o. daily. A loading dose of 600 mg of clopidogrel is given to
DAPT naïve patients or 300 mg to patients previously on clopidogrel.
This is then continued with 75 mg of clopidogrel p.o. daily. The DAPT
is maintained for 6 months for SCAD and for a year for acute coronary
syndromes. The cardiology unit does not have access to prasugrel,
ticagrelor, bivalirudin and GP IIb/IIIa inhibitors. Unfractionated
heparin at a dose of 70–100 U/Kg was the anticoagulation therapy
used during PCI.
The third universal definition of myocardial infarction Type 4 was
used to define PMI [7]. The primary end-point (peri-procedural
myocardial infarction) was considered when the 16–24-h post PCI
cardiac biomarker was elevated by more than five times the 99th
percentile upper reference limit (URL) for the local laboratory. This
cut-off valuewas used for patients who had a normal cardiac biomarker
baseline (pre-PCI troponin b99th URL). A new elevation in the cardiac
biomarker, of N20% of the baseline, was used as a “rule –in” criteria for
patients who demonstrated a cardiac biomarker level that was elevated
above the 99th percentile URL at baseline, but stable or declining on
serial measurements prior to the diagnostic coronary angiography [7].
A diagnosis of PMI was then confirmed by the presence of new
periprocedural & post-procedural ischaemic ECG changes or with
identifiable angiographic findings consistent with a procedural
complication [7].
According to the third universal definition of myocardial infarc-
tion type 4a, demonstrating early troponin rise is not as critical as
the peak troponin level reached (compared to the baseline troponin
level) in order to rule-in a possibility of PMI. The diagnosis of PMI
does not solely rely on the initial cardiac biomarker elevation, in-
stead it compares the magnitude of maximal elevation to baseline
levels [7]. A cardiac biomarker measurement strategy designed to
detect the peak cardiac biomarker level is therefore more appropri-
ate, and likely to yield more positive results of PMI detection. Based
on this rationale, we decided to do cardiac biomarker measurements
at 16–24 h post PCI. This strategy has also been successfully used by
Zemanek et al. [8].
Patient characteristics were assessed by a detailed medical history
and physical examination performed during hospitalisation. PCI was
performed according to current guideline management recommenda-
tions [5]. The number of treated lesions, duration of inflations, inflation
pressure and type of stent were determined individually by the opera-
tors. Interventional success was defined as final angiographic residual
stenosis b20% of the vessel diameter based on quantitative angiograph-
ic evaluation and thrombolysis in myocardial infarction (TIMI) III grade
coronary flow.
All clinical, laboratory and angiographic data were assessed and
quantified by an independent research team including an experienced
cardiologist. The studywas approved by the local university ethics com-
mittee and complies with the Declaration of Helsinki. All study
participants gave written informed consent before participation.
2.2. Statistical analysis
All statistical analyses were generated using STATA version 13.1
(StataCorp, Texas). Continuous variables were expressed as mean ±
standard deviation (SD) or as medians and interquartile ranges and
discrete variables reported as percentages. Odds ratios (OR) are pre-
sented along with their 95% confidence interval (CI). A 2–tailed p
value of b0.05 was considered statistically significant. Differences be-
tween groups were assessed using the unpaired Student t-test for
continuous variables. Categorical variables were analysed using the
Chi-square test. Both univariate and multivariate logistic regression
analyses were performed. The following parameters were included
in the multivariate logistic regression analysis: age, duration of proce-
dure, right coronary artery intervention, C-reactive protein and total
stent length. These variables were selected according to known im-
portant risk factors for PMI. Study data were collected and managed
using REDCap (Research Electronic Data Capture) electronic data cap-
ture tools hosted at the University of the Witwatersrand, Johannes-
burg, South Africa [9].
3. Results
During the 10-month study period 153 participants were recruited.
One patient was excluded from the analysis due to a laboratory techni-
cal error. (Fig. 1).
Using the third universal definition of myocardial infarction related
to PCI (Type 4a), the incidence of PMI in this study was found to be
10.5% (n = 16). There were no significant demographic or anthropo-
metric differences between those who developed PMI and those who
did not (Table 1).
Themean age of the study population was 58.8 (SD 10.9) years, 70%
of whom were men. There were only 29 (19.1%) black participants in
the overall study population. The baseline clinical characteristics in
those with and without PMI were also comparable with no significant
differences (Table 2). The duration of hours from the onset of reported
chest pain to the start of coronary angiography were 43.9 (22.5–
126.25) and 106.5 (47.7–106.5), median and interquartile ranges for
the STEMI and NSTEMI subgroups, respectively. The procedural results
are summarised in Table 3.
Multivariate analysis (Table 4) was performed to identify
independent predictors of PMI. In this model, none of the
variables showed statistical significance for association with PMI. Of
the 16 patients with PMI, 10 of these had side branch compromise, 2
had acute stent thrombosis, 2 distal embolisation and 2 had a flow lim-
iting coronary dissection (Table 5). Table 6 summarises the ECG changes
that were associated with these complications.
There were only 2 deaths during PCI which were associated with
PMI. The first was a 80 year old male with a high risk non-ST segment
elevation myocardial infarction. Coronary angiography revealed triple
vessel disease with a SYNTAX score [10] of 29. He declined coronary
artery bypass grafting and underwent multivessel PCI of his left
circumflex (LCx) and left anterior descending (LAD) coronary artery.
While PCI of the proximal LAD artery was being performed, he
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complicated with hyper-acute stent thrombosis of his left circumflex
artery. Despite revascularisation of the circumflex artery, he deteriorat-
ed and demised.
The secondwas a 42 year old female who presented with an inferior
ST segment elevation myocardial infarction due to acute stent
thrombosis (PCI performed 9 days previously) from poor compliance
to antiplatelet therapy. Coronary angiography revealed total occlusion
of theproximal right coronary artery (RCA)with high thrombus burden.
Revascularisation of her RCA complicated with proximal and distal
thrombus embolisation. She arrested and cardiopulmonary resuscita-
tion was unsuccessful.
4. Discussion
The present study is the first systematic study in Sub-Saharan Africa
investigating the incidence of PMI according to the third universal
Total number of state patients undergoing PCI from 01 February 2014 to 
31 October 2014
(n= 222)
Patients recruited into the study for evaluation for PMI
(n= 153)
Patients analysed for PMI
Meeting all inclusion criteria
(n= 152)
PMI not diagnosed
(n= 136)
PMI diagnosed
(n= 16)
1 patient excluded from analysis
Post PCI cardiac biomarker not 
processed in the laboratory, due to a 
technical error
Fig. 1. Flow chart of the study.
Table 1
Baseline demographic and anthropometric characteristics of patients according to peri-procedural myocardial infarction.
Variable Overall population
(n = 152)
Peri-procedural Myocardial Infarction p value
No (n = 136) (89.5%) Yes (n = 16) (10.5%)
Age (years) 58.8 SD 10.9 58.5 SD 10.7 62.0 SD 11.8 0,220
Gender: 0,879
Male 107 (70.4) 96(70.6) 11(68.8)
Ethnicity 0,316
White 64 (42.1) 59(43.4) 5(31.3)
Indian 47 (30.9) 39(28.7) 8(50.0)
Black 29 (19.1) 26(19.1) 3(18.8)
Mixed Ancestry 12 (7.9) 12(8.8) 0(0.00)
Height (meters) 1.7 SD 0.1 (n = 142) 1.7 SD 0.1 (n = 126) 1.7 SD 0.1 0,849
Weight (kilograms) 77.7 SD 17.8 (n = 147) 77.4 SD 17.3 (n = 131) 80.1 SD 21.9 0,561
BMI (kg/m2) 28.0 SD 6.3 (n = 142) 27.9 SD 6.4 (n = 126) 28.6 SD 5.7 0,665
BSA (m2) 1.9 SD 0.2 (n = 142) 1.9 SD 0.2 (n = 126) 1.9 SD 0.3 0,638
Data are shown as mean, standard deviation (SD) for continuous variables and absolute numbers (percentage) for dichotomous variables.
BMI, body mass index; BSA, body surface area.
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definition of myocardial infarction [7]. Despite operating in a resource
limited centre with restricted access to newer antiplatelet agents and
novel coronary imaging modalities which have been shown to prevent
and better predict PMI [11–14], the incidence of PMI in our cohort was
10.5%. This is consistent with the prevalence of PMI internationally. Our
findings are reassuring in light of the increasing frequency of PCI being
performed in our population.
Duration of procedure, total stent length and RCA intervention
were the only risk factors associated with the development of PMI.
In our study a longer duration of procedure could have been an indi-
rect measure of lesion complexity or a measure of interventional op-
erator competence. However, in our analysis we did not find an
association between coronary artery lesion complexity and PMI.
This has been demonstrated by Van Gaal et al. [15] who showed
that a higher incidence of PMI correlated with a higher Syntax
score [10]. Hoole et al. [16] has previously demonstrated the associ-
ation between coronary artery stent length and PMI.
A recently published systematic review on predictors of PMI based
on 11 prospective PCI studies with 23,604 patients, also found that
higher lesion and procedural-related risk profiles were associated with
PMI [17]. Left anterior descending artery disease, left main disease, bi-
furcation lesions, lesions (N20 mm) and number of stents deployed
were found to be independent predictors of PMI [17]. These risk factors
have been associated with a greater incidence of side branch occlusion
(type 1 PMI) and structural or functional microvascular obstruction
(type 2 PMI) [18–20].
Our study is unique in that we found revascularisation of the RCA to
be associated with PMI. Previous studies have not observed this associ-
ation [17]. PCI of the RCA is generally thought to be less complicated
than that of the other coronary arteries. Of the 16 patients with PMI, 9
involved interventions of the RCA. Of these 5were related to side branch
compromise; 2 patients had distal embolisation; 1 had a flow limiting
dissection and 1 patient had an acute stent thrombosis. In our cohort,
the low threshold to stent across side branches in the RCA probably
accounts for our findings that RCA interventions are associated with
PMI.
In this study side branch compromise was observed in 62.5% of all
cases complicating with PMI. This finding is well documented in
previous studies and is thought to be related to the length of the
carina, carina deformation and plaque shift [21,22]. The determina-
tion of fractional flow reserve in a compromised side branch after
main branch stenting has previously shown that generally these
lesions are not physiologically significant [23]. Despite this finding,
side branch compromise remains the most common cause of PMI
[17,24].
Although our unit provides a clinical service to a predominantly
black population, only afifth of the studypopulationwasblack. This cor-
relates with previously published African CAD data suggesting that the
prevalence of CAD in black African people is relatively low compared
to their white and Indian counterparts [25,26]. However as more black
African people become urbanised their risk of developing CAD has in-
creased compared to reported data from non-urbanised black African
communities [27].
The human immunodeficiency virus (HIV) infection is highly
prevalent in South Africa [28]. It has been shown that HIV positive
patients taking anti-retroviral medication have an increased risk of
developing CAD [29,30]. In our study only 4 participants were HIV
positive and none of them developed PMI. The anticipated increased
burden of CAD due to HIV and combination antiretroviral therapy
(cART) has thus far not been noticed in our population. This could
be related to the very low prevalence of CAD amongst the black pop-
ulation despite the high prevalence of HIV and increasing access to
cART.
The study limitations include a relatively small sample size. There is
also the possibility, albeit very unlikely, ofmissing cardiac biomarker el-
evation in the interval from PCI to biomarker evaluation 16–24 h later.
Table 2
Baseline clinical characteristics of patients according to periprocedural myocardial infarction.
Variable Overall population (n = 152) Peri-procedural Myocardial Infarction p value
No (n = 136) (89.5%) Yes (n = 16) (10.5%)
CRP (mg/L) 9 ( 4–45) (n = 141) 9 (4–48) (n = 126) 12 (4–19) (n = 15) 0,580
TIMI Score 3.6 SD 1.7 (n = 122) 3.6 SD 1.7 ( n = 113) 3.1 SD 1.2 (n = 9) 0,369
WCC (109/L) 10.5 SD 3.7 (n = 149) 10.6 SD 3.8 (n = 133) 9.2 SD 2.5 0,152
Total Cholesterol (mmol/l) 4.2 SD 1.3 4.3 SD 1.3 3.6 SD 1.3 0,055
HDL-C (mmol/l) 0.9 SD 0.3 (n = 151) 0.9 SD 0.3 (n = 135) 0.8 SD 0.3 0,334
LDL-C (mmol/l) 2.6 SD 1.0 (n = 148) 2.7 SD 1.0 (n = 132) 2.2 SD 1.0 0,142
Pre PCI eGFR (ml/min/1.73m2) 90.5 SD 30.8 (n = 146) 91.1 SD 31.0 (n = 130) 85.7 SD 30.3 0,515
16–24 h Post PCI eGFR (ml/min/1.73m2) 84.8 SD 29.1 (n = 140) 85.2 SD 30.0 (n = 129) 79.5 SD 16.0 (n = 11) 0,534
Admission LVEF (%) 51.6 SD 12.1 (n = 148) 51.6 SD 11.9 (n = 133) 51.3 SD 14.3 (n = 15) 0,932
Diabetes mellitus 38(25.0) 33(24.3) 5(31.3) 0,542
HBA1c 9.4 SD 2.3 (n = 32) 9.7 SD 2.4 (n = 27) 7.7 SD 1.2 (n = 5) 0.084
Hypertension 97(63.8) 86(63.2) 11(68.8) 0,664
HIV Positive 4(2.6) 4(2.9) 0(0.00) 0,487
Current Smoker 99(65.1) 92(67.6) 7(43.8) 0,058
NYHA Classification 0.622
I 115(75.7) 102(75.0) 13(81.3)
II 30(19.7) 28(20.6) 2(12.5)
III 2(1.3) 2(1.5) 0(0.0)
IV 5(3.3) 4(2.9) 1(6.3)
Acute coronary syndrome 119(78.3) 110(80.9) 9(56.2) 0,707
STEMI 86(56.6) 80(58.8) 6(37.5)
NSTEMI 33(21.7) 30(22.1) 3(18.8)
Non-acute coronary syndrome 33(21.7) 26(19.1) 7(43.8) 0,523
Concomitant medications
Beta blockers 85(55.9) 73(53.7) 12(75.0) 0,119
ACE inhibitor 88(57.9) 77(56.6) 11(68.8) 0,353
Statins 115(75.7) 103(75.7) 12(75.0) 0,948
Calcium channel blocker 17(11.2) 14(10.3) 3(18.8) 0,310
Data Data are shown as mean, standard deviation (SD) for continuous variables and absolute numbers (percentage) for dichotomous variables.
CRP, C-reactive protein; TIMI, thrombolysis in myocardial infarction; WCC, white cell count; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; HBA1c,
glycated haemoglobin; ACE, angiotensin converting enzyme.
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The small sample size with a low expected incidence of PMI in PCI, may
be associated with a potential statistical type II error.
5. Conclusion
The results of this single centre, prospective observational study
has found an incidence of PMI to be 10.5%. Despite being in a
resource limited environment this is consistent with the prevalence
of PMI internationally. Larger multicentre studies are required in our
demographic region to further define relevant predictors and
outcomes of PMI.
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Table 3
Angiographic and interventional characteristics of patients according to periprocedural myocardial infarction.
Variable Overall population (n = 152) Peri-procedural myocardial infarction p value
No (n = 136) (89.47%) Yes (n = 16) (10.53%)
Pre-PCI Systolic BP (mmHg) 133.0 SD 29.6 133.8 SD 30.3 126.1 SD 22.9 0,324
Pre-PCI Mean BP (mmHg) 97.1 SD 20.0 97.3 SD 20.3 96.3 SD 17.8 0,851
Framingham 10 Year Risk (%) 13.6 SD 9.2 (n = 151) 13.9 SD 9.4 (n = 135) 10.7 SD 7.4 0,186
Duration of Procedure (minutes) 87.8 SD 30.8 85.6 SD 28.8 107.2 SD 40.3 0,007
Total Stent Length (mm) 25.0 SD 10.5 (n = 147) 24.5 SD 10.0 (n = 132) 30.1 SD 13.5 (n = 15) 0,050
Contrast Media Used (ml) 260.0 SD 77.0 (n = 151) 257.3 SD 78.9 (n = 135) 283.1 SD 54.5 (n = 16) 0,205
Duration of Hospital Stay (days) 3.8 SD 3.3 3.9 SD 3.4 3.4 SD 2.4 0,614
Coronary artery disease distribution (n = 152) (n = 136) (n = 16) 0,677
Single vessel disease 82(54.0) 75(55.2) 7(43.8)
Double vessel disease 45(29.6) 39(28.7) 6(37.5)
Triple vessel disease 25(16.5) 22(16.2) 3(18.8)
Coronary artery treated
LMCA 1(0.7) 1(0.7) 0(0.00) 0,731
LAD 74(48.7) 67(49.3) 7(43.8) 0,676
LCx 29(19.1) 27(19.9) 2(12.5) 0,738
RCA 51(33.6) 42(30.9) 9(56.3) 0,042
Other CAD 10(6.6) 9(6.6) 1(6.3) 0,955
Coronary artery lesion site
Ostial 3(2.0) 3(2.2) 0(0.00) 0,548
Proximal 79(52.0) 69(50.7) 10(62.5) 0,373
Mid Vessel 75(49.3) 66(48.5) 9(56.3) 0,559
Distal 24(15.8) 22(16.2) 2(12.5) 0,703
Coronary artery lesion complexity (n = 152) (n = 136) (n = 16) 0,196
A 29(19.1) 28(20.6) 1(6.3)
B 115(75.7) 100(73.5) 15(93.8)
C 8(5.3) 8(5.9) 0(0.00)
Stent choice
Drug Eluting Stent 141(92.8) 126(92.7) 15(93.8) 0,872
Bare Metal Stent 1(0.7) 1(0.7) 0(0.00) 0,731
Drug Eluting Balloon 15(9.9) 14(10.3) 1(6.3) 0,608
Other Stent 1(0.7) 1(0.7) 0(0.00) 0,731
Intervention success 0,241
TIMI III flow and good angiographic result 143(94.1) 129(94.9) 14(87.5)
Data are shown as mean, standard deviation (SD) for continuous variables and absolute numbers (percentage) for dichotomous variables.
PCI, percutaneous coronary intervention; BP, blood pressure; LMCA, left main coronary artery; LAD, left anterior descending artery; LCx, left circumflex artery; RCA, right coronary artery;
CAD, coronary artery disease.
Table 4
Multivariable logistic regression analysis independent predictors of periprocedural myo-
cardial infarction.
Variables OR 95% CI Z p value
Age (years) 1,01 0.95–1.07 0,35 0,728
Smoking (Yes) 0,62 0.18–2.12 -0,76 0,447
Duration of procedure (min) 1,02 0.99–1.04 1,89 0,059
Right coronary artery intervention 2,25 0.69–7.29 1,35 0,178
C– Reactive protein (mg/L) 0,98 0.95–1.00 -1,39 0,163
Total stent length (mm) 1,01 0.96–1.07 0,4 0,691
Abbreviations: CI, confidence interval; OR, odds ratio; min, minutes.
Table 5
Causes of periprocedural myocardial infarction.
Complication No of patients (n = 16)
Side branch compromise 10 (62.5)
Acute stent thrombosis 2 (12.5)
Distal embolisation 2 (12.5)
Flow limiting coronary dissection 2 (12.5)
All data presented as number (%).
Table 6
Persistent ischaemic periprocedural ECG changes.
Complications (n = 16)
Total no of patients with ECG changes
(n = 6)
Side branch compromise(10) 3 (30)
Acute stent thrombosis (2) 2 (100)
Distal embolisation(2) 1 (50)
Flow limiting coronary dissection
(2)
0 (0)
All data presented as number (%).
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1. Introduction and Extended Literature Review 
 
1.1 Introduction 
The very first coronary artery balloon angioplasty is reported to have been performed 
by Gruntzig in 1977.1 Subsequently to this, over the past 40 years, there have been 
significant advances in coronary angiography and intervention. Coronary artery 
interventional techniques have evolved and improved significantly. There have been 
considerable device developments, new generation stents and novel antiplatelet 
therapy which have all proved to reduce the incidence of the primary periprocedural 
complications associated with percutaneous coronary intervention (PCI).2,3 Despite 
these significant advances, periprocedural myocardial infarction remains a common 
complication of PCI.4 
 
Coronary heart disease is predicted to remain the number one cause of morbidity 
and mortality worldwide until the year 2030, and beyond.5 This emerging epidemic is 
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also exponentially increasing in the developing world, where urbanisation has 
occurred.6 Percutaneous coronary intervention has become a prominent therapeutic 
procedure for atherosclerotic coronary artery disease.7 In sub-Saharan Africa the 
use of this method is also increasing, yet there is no regional data on the safety and 
complications associated with this procedure.8 
 
1.2 Definition and diagnosis of periprocedural myocardial infarction (PMI) 
 
The definition of PMI has been revised multiple times since its original description. 
Over the years, it has been modified by changing the preferred cardiac biomarker 
used to make a diagnosis of PMI and different peak cardiac biomarker elevations 
were proposed to rule in PMI.9,10 The current definition of PMI is from the third 
universal definition of myocardial infarction. This definition was published in 2012.10 
According to this definition; you may diagnose PMI (Type 4a MI) when there is a post 
procedural increase of a cardiac biomarker greater than five times the 99th 
percentile upper reference limit (URL) within 24 to 48 hours after the procedure.10 A 
non-elevated baseline (pre-procedural) cardiac biomarker value is required to use 
this definition.  
 
The global task force recommends the use of highly sensitive cardiac troponins (hs-
cTnI or cTnT) to creatinine kinase myocardial band (CK-MB) for the definition of 
acute myocardial infarction.10-12 Cardiac troponins are reported to have an increased 
sensitivity and specificity than CK-MB and therefore have a better diagnostic 
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yield.13,14 Use of these overly sensitive tests to detect myocardial injury after PCI can 
be challenging as small increases from the baseline in biomarker levels after PCI are 
expected and do not necessarily represent a complication.15,16 
 
Criteria for a new periprocedural injury have also been proposed based on a new 
troponin rise after an apparently falling pre-procedural pattern. If the baseline 
troponin is elevated, yet stable or decreasing, a new increase of > 20 percent can be 
used to define a periprocedural MI event.10,17 The clinical challenge is evident when 
a patient presents with ST - segment elevation MI (STEMI) and undergoes primary 
PCI. In some of these patients, cardiac biomarkers are not yet elevated or are still 
rising, thus making it difficult to differentiate whether the elevation is due to the index 
STEMI or caused by the PCI procedure. Following PCI, an elevation of either 
troponin or CK-MB above the upper limits of normal has a worse short and long term 
prognosis.18,19 
 
Over the years, the reliance on cardiac biomarkers alone to clinch a diagnosis of PMI 
has been abandoned.10 The third universal definition requires that patients should 
have at least one of the following also: 
i) Symptoms in keeping with myocardial ischaemia 
ii) New ischaemic electrocardiography changes 
iii) Coronary angiographic findings suggestive of a procedural complication 
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iv) demonstrating a new loss of viable myocardium or new regional wall motion 
abnormality on cardiac imaging. 
Depending on the consensus definition used at the time of data collection, the 
incidence of PMI has varied considerably.20 The recommended choice of a cardiac 
biomarker used, peak cut-off value used and frequency of blood sampling for cardiac 
biomarker analysis, all affected the reported incidence of PMI.21 A recently published 
large meta-analysis reported an incidence of seven percent measured by CK-MB.4 
 
1.3 Risk factors for Periprocedural Myocardial Infarction 
 
1.3.1 Patient-specific risk factors for periprocedural myocardial infarction 
The total atherosclerotic burden carried by the patient is an important risk factor for 
PMI. Generalised atherosclerosis, diffuse coronary artery disease (CAD) and 
multivessel CAD are all associated with an increased incidence of PMI.4  Advancing 
age, chronic kidney disease and anaemia have all been confirmed to promote PMI.22 
Implicated markers of inflammation include a raised pre-procedural C-reactive 
protein and white blood cell count.23,24 
 
1.3.2 Coronary artery lesion risk factors for periprocedural myocardial infarction 
Coronary artery disease risk factors include the left main artery and proximal left 
anterior descending artery interventions. Furthermore, the more complex the lesion, 
such as type C lesions and a higher syntax score, the greater the association with 
5	
	
PMI.4 This is most likely due to prolonged and challenging catheter manipulation 
required to treat the lesion percutaneously successfully. Due to their friable calibre, 
saphenous vein graft interventions are also responsible for causing PMI.22 
 
1.3.3 Coronary artery interventional risk factors for PMI 
Procedural factors associated with PMI include multivessel PCI, atherectomy, side 
branch occlusion, dissection, increased thrombus burden, slow flow/no-reflow 
phenomenon and distal embolisation.20 In line with the third universal definition of 
myocardial infarction, angiographic complications are the most frequently listed and 
strongest predictors of PMI.4 
 
1.4 Pathophysiology of periprocedural myocardial infarction 
Coronary artery interventions by their very nature cause plaque disruption, 
redistribution, compression and fragmentation. This vessel injury causes 
atherosclerotic micro emboli which have the potential to cause distal embolism and 
occludes the epicardial and myocardial microvascular tree.25 PMI has two primary 
forms: 
Type 1 – Proximal-type PMI. This type of PMI is mainly due to side branch occlusion 
of an epicardial artery and is in proximity to the treated atherosclerotic lesion.25 
Type 2 – Distal type PMI. This type of PMI is the most common mechanism of PMI. It 
is due to structural and functional microvascular obstruction of the distal coronary 
tree. It occurs distal to the treated atherosclerotic lesion.25 
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1.5 Treatment and prevention of periprocedural myocardial infarction 
There are multiple therapies for the prevention of PMI. These include the use of 
antiplatelet drugs,24,26 statins,27,28 ischaemic preconditioning, use of adenosine as 
well as distal embolic protection devices.22 
The treatment of peri-procedural MI depends upon identifying and treating the 
underlying cause. Periprocedural MI is usually silent and not diagnosed during the 
procedure, but recognised afterwards if cardiac enzymes are routinely measured.10 
Supportive measures alone are adequate for 1 to 5-fold increase in cardiac 
biomarker.4 Q- wave infarcts and those with CK-MB or troponin >5 URL need 
coronary intervention therapy. Treatment should follow guidelines for the 
management of spontaneous STEMI and non-STEMI.25 
 
1.6 Long-term prognosis of periprocedural myocardial infarction 
A correlation exists between PMI and future major adverse cardiac events (MACE).13 
Cardiovascular mortality is proportionally related to the increase in cardiac biomarker 
level. Post-procedural cardiac biomarker levels > 5 URL are considered significant.29 
The latest criteria for diagnosing PMI is the strictest to date and requires the 
presence of a confirmed complication to diagnose PMI. This definition is likely to 
improve the association of PMI and MACE outcomes further.30 
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On average, the Charlotte Maxeke Johannesburg Academic Hospital cardiology unit 
performs 3 to 4 PCIs per week. Despite this high hospital and operator volume, our 
local incidence of periprocedural MI still needs to be determined. The aim of our 
study is therefore to define our local rate of peri-procedural MI. To describe the 
relevant risk factors identified in our patients undergoing PCI and to correlate our 
outcomes with the observed levels of cardiac biomarkers and to compare our 
findings to other centres abroad. 
 
2. STUDY OBJECTIVES 
1. Define the incidence of peri-procedural MI at CMJAH. 
2. To identify key risk factors associated with peri-procedural MI. 
3.  To correlate outcomes with the observed levels of cardiac biomarkers. 
4. To compare our incidence rate of peri-procedural MI to other centres. 
 
3. METHODS 
3.1 Study Design 
This will be a prospective review of clinical data of all patients undergoing PCI over a 
6-month period at Charlotte Maxeke; with analytical and descriptive elements. 
 
3.2 Study Population and Samples 
This study will be conducted in the division of cardiology at the Charlotte Maxeke 
Academic Hospital in Johannesburg. Data will be collected from all patients 
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undergoing PCI in the catheterisation laboratory over a 6-month period targeting a 
sample size of 100 patients. The study may continue beyond 6 months until a 
minimum of 100 patients has been reviewed.  The population under study is all adult 
(above 18 years). The sample size will be dependent on the total number of patients 
on whom PCI is performed. 
 
3.3 Eligibility Criteria 
All patients in whom PCI is done are eligible for this study. A baseline cardiac marker 
is required before PCI. The trend will then be followed post PCI at 16 to 24 hours. 
Increases of biomarkers greater than 5 X 99th percentile URL will be used to define 
PCI – related MI (type 4a).10 This is in line with the Universal definition of Myocardial 
infarctions which has been endorsed academic societies & regulatory bodies. Patients 
with an elevated cardiac biomarker >99th percentile URL; myocardial re-infarction is 
defined by a new rise of >20% in serum biomarkers over the last nadir.10 This meets 
criteria for differences in analytical values (>3SD difference of the variance of the 
measure). 
 
3.4 Study Tools 
All bed letter records/information for the patients undergoing PCI will be identified. 
Data collection sheets will be used to obtain information from the bed letter. (See 
appendix) 
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3.5 Variables 
Risk Factors for Developing Periprocedural Myocardial Infarction (PMI) 
 
Patient Factors: 
1. Age, gender, ethnicity 
2. Co-morbidities: diabetes, hypertension, chronic kidney disease, HIV, peripheral 
vascular disease, dyslipidaemia, family history of ischaemic heart disease, previous 
MI, smoking. 
3. Clinical presentation: NYHA, STEMI, NSTEMI, TIMI score, C-reactive protein, White 
cell count, Total cholesterol, LDL, creatinine, CK-MB, Trop I, Left ventricular ejection 
fraction and pre-angiogram blood pressure.  
4. Concomitant medications: B-blockers, ACE inhibitors, HMG CoA reductase 
inhibitors, calcium antagonists, ATII antagonists, thrombolytics. 
 
Angiographic Lesion Factors: 
1. Distribution of CAD: single, double or triple vessel disease. 
2. Vessel treated: Left main, LAD, LCx, RCA, other branches. 
3. Lesion Site: Ostial, proximal, midvessel, distal. 
4. Number of treated vessel/patient 
5. Number of treated lesion/patient 
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6. Multivessel PCI 
7. Complex lesions (B2/C) 
 
Procedural Factors: 
1. Duration of procedure 
2. Major dissection / perforation 
3. Significant spam / slow / no reflow  
4. High thrombus burden 
5. Side-branch closure / compromise 
6. Distal embolisation 
7. Type of stent used. 
8. Total length of stent (mm) 
9. Total contrast agent (ml) 
10. Successful PCI (%) 
Cardiac Biomarkers  
Trop I & CK-MB levels: pre-PCI, and at 16 to 24hrs Post PCI. 
Duration of hospital stay (days) 
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4. DATA ANALYSIS: 
Data will be presented as mean + 2SD, median and interquartile range, or as a 
percentage, as appropriate. Descriptive statistics-frequency tables; pie charts; bar 
graphs will be used to describe demographic and clinical characteristics. Chi-test and 
Fisher’s exact will be used for categorical data, student t- test for normally distributed 
continuous variables and Wilcoxon rank sum test (parametric test) for non-normal 
continuous data. Continuous variables will be tested for normality using histograms 
and normal quartile plots. STATA version 11 will be used for the data analysis 
 
5. ETHICS 
This study will be conducted at Charlotte Maxeke Academic Hospital in the 
Department of Cardiology in fulfilment of the requirements of the Master of Medicine 
degree research report. Ethics approval will be sought from the University of 
Witwatersrand Human Research Ethics Committee and relevant hospital authorities. 
Written informed consent will be sought from all patients before they participate in the 
study. Unique patient identifiers will be used on the data collection sheet to protect the 
identity of the study participants. Findings will be published in an academic journal and 
will be used to improve patient care in the Department of cardiology at Charlotte 
Maxeke Academic Hospital. 
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6. TIMING 
TASKS PROPOSED COMPLETION DATE 
Protocol assessment August 2012 
Ethics Application September 2012 to October 2012 
Data Collection November 2012 to May 2014 
Data analysis June to July 2014 
Write up - thesis July to September 2014 
Write up - paper September to October 2014 
  
  
7. FUNDING 
This study is a low-cost research project. The student will be able to meet the running 
expenses which include stationary and printing. Courses organised by the university 
to help with data analysis and writing up of the thesis will be attended by the student. 
In the majority of cases presenting with acute/sub-acute ACS it is routine practice to 
request baseline biomarkers pre-and post-procedure. However, those patients 
presenting from home for an elective PCI; a baseline cardiac enzyme is not part of 
routine care. The costs for these biomarker levels pre-procedure will be incurred by 
the department of cardiology. 
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INFORMED CONSENT 
Study Title: PERIPROCEDURAL MYOCARDIAL INFARCTION FOLLOWING PERCUTANEOUS CORONARY 
INTERVENTION AT CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC HOSPITAL 
 
Setting:  Charlotte Maxeke Johannesburg Academic Hospital 
  Cardiology Unit 
           Investigator:  Dr Tsabedze Nqoba I    Cell phone Number: 072 272 2420 
  University of Witwatersrand  Email address: nqobat@yahoo.com 
Hello my name is Dr Tsabedze, I am a Masters student specialising in cardiology. As part of my degree requirements I have to 
do a research report that involves a review of the hospital files for patients with the condition I am investigating. I am asking for 
your permission to include your file in this research study. You have been selected because your blood vessels supplying blood 
to your heart are blocked and you are scheduled to undergo a procedure to open up these arteries. I would like to review your file 
to see whether there were any procedure related complications. I would also look at what risk factors you may have had that 
could have suggested to us that you are likely to have a complication.  
What is the study about? 
I am planning on reviewing a minimum of 100 patient files. I will not interfere with the patients’ routine care in the ward. I will 
assess file data to ascertain what form of intervention was done and whether a complication occurred or not. The following 
information will be retrieved from your file: Age; gender; ethnicity; other illnesses you may have; the clinical presentation; 
concomitant medications used; angiographic lesion factors; procedural factors; baseline and post procedure cardiac biomarkers; 
as well as duration of hospital stay.  
Why is the study being done? 
This study will enable us to define how many patients who undergo coronary intervention develop a complication in our unit. 
We will be able to identify key risk factors relevant to our unit associated with developing coronary intervention complications. 
We will be able to compare our incidence rate of procedural complications to other centers local and international. With this 
information we can then try and find ways of reducing the risk of procedural complications in our unit and for other centers. 
Please note: 
There are no risks involved in participating in this study as we are only reviewing data from your file. The decision for us to use 
your file is voluntary. Information obtained will be confidential and that which is reported will not identify you as a participant in 
this study. There are no reimbursements for allowing us to use your file data and there will be no monetary expenses incurred by 
you either. We will not change your management strategy we are simply reviewing your file records. This study has been 
approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand, Johannesburg. 
Their contact details are: Tel. 011 717-1234, Fax no. 011 717 1265. E-mail: anisa.keshav@wits.ac.za. 
 
 
I have read this document and fully understand its contents. 
I __________________________________________________ grant permission for my file to be used 
in this study. 
Sign: ______________________________                                    Witness:  Dr N. Tsabedze 
    Date: _________________________                         Date: ______________ 
                                    
 
 
     Study Form No.             
                 
PERIPROCEDURAL MYOCARDIAL INFARCTION FOLLOWING     
PERCUTANEOUS CORONARY INTERVENTION AT CHARLOTTE MAXEKE  
JOHANNESBURG ACADEMIC HOSPITAL.          
                 
DATA COLLECTION SHEET:              
                 
Date of data collection:                       
                 
Demographic Data:               
                 
Age at time of PCI (years)                 
                 
Gender (male = 1; female = 2)               
                 
Self Identified Ethnic Group               
( African = 1; Indian = 2; White =3; Coloured =4)         
                 
                 
Patient Risk Factors               
Co-morbidities:                    
                 
(Diabetes=1; Hypertension =2; CKD=3;               
HIV=4; PVD=5; Dyslipidaemia=6;              
Family Hx=7; Previous MI=8; Smoking=9               
Other=10; None = 11)               
                 
Clinical Presentation               
                 
New York Heart Association Class             
                 
Acute Coronary Syndrome:              
STEMI=1; NSTEMI=2                
                 
Non ACS Symptoms:                
(Asymptomatic=1; Stable angina = 2;            
Unstable angina = 3)               
                 
TIMI Score:                 
                 
C-reactive protein on admission:                
                 
White cell count on admission:                 
                 
Total Cholesterol (mmol/l)                  
                 
                 
LDL Cholesterol (mmol/l)                 
                 
Serum Creatinine (umol/l)                 
                 
Creatine Kinase MB:               
Baseline value (Pre-PCI)                  
Value at 16 to 24hrs Post PCI                 
                 
Troponin - I:                
Baseline value (Pre - PCI)                     
Value at 16 to 24hrs Post PCI                    
                 
Left Ventricular Ejection Fraction (%)               
                 
Pre-PCI Mean Arterial Pressure(mmhg)              
                 
Concomitant Medications:               
(B-blockers = 1; ACE inhibitors = 2; Statins = 3;              
Calcium antagonists = 4; ATII antagonists = 5;         
Prior use of thrombolytics =6;                  
None = 7)                
                 
Angiographic Lesion Factors:              
                 
Distribution of CAD:                
(Single vessel = 1; Double vessel = 2            
Triple vessel =3)                
                 
Vessel Treated:                   
(Left main = 1; LAD = 2; LCx =3; RCA = 4;          
Other = 5)                  
                 
Lesion Site:                
(Osteal = 1; Proximal = 2; Midvessel = 3;               
Distal = 4)                
                 
                 
Lesion Complexity:                
(A = 1; B = 2; C = 3)               
                 
Syntax Score:                    
                 
                 
                 
Procedural Factors:               
                 
Duration of procedure (minutes):                
                 
Complications:                   
( Major dissection / perforation = 1;             
Slow / no reflow = 2;                  
Significant spasm = 3;               
High thrombus burden = 4;                
Side branch closure / compromise = 5;           
Distal embolisation = 6; None = 7)             
                 
Stent Choice:                    
( Drug eluting stent = 1;               
Drug eluting ballon = 2;               
Bare metal stent = 3;               
Other = 4)                
                 
Total Stent Length (mm)                   
                 
Total Volume of Contrast Used (ml)                
                 
PCI Success:                
TIMI III Flow & good angiographic result = 1;           
Other = 2)                
                 
Duration of Hospital Stay ( days) :                
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